Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 37811776.
- Also identified by DOI 10.14309/ajg.0000000000002490.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of -6.9 ± 8.3 and -8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.